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 The role of lymph node dissection (LND) for non-small cell lung cancers remains 
controversial. 
 LND adds little morbidity to a pulmonary resection for NSCLC although it requires 
additional operative time by 15-20 min. 
 Four prospective randomized trials have been performed to compare lymph node 
sampling (LNS) and LND; three trials showed no difference in survival and one 
trial showed survival benefit of LND. 
 The largest prospective randomized trial ACSOG Z0030 clearly demonstrated that 
LND does not improve long-term survival in patients with early-stage (T1 or T2, N0 
or non-hilar N1) NSCLC who have pathologically negative lymph nodes after 
rigorous systematic LNS. 
 It is recommended that all patients with resectable NSCLC should undergo LND 
because the procedure provides the patients with the most accurate staging and the 






It is well known that metastasis to hilar or mediastinal lymph node, the N factor, is 
one of the most important determinants of prognosis after lung cancer surgery (1-3). 
However, the role of lymphadenectomy in the staging and treatment of non-small cell 
lung cancer (NSCLC) remains controversial. Current surgical practice varies from 
visual inspection of the unopened mediastinum to systemic lymph node dissection. 
Systematic mediastinal lymph node dissection, as practiced by Japanese surgeons, is a 
much more extensive operation than that practiced by North American surgeons. Little 
and colleagues surveyed 729 hospitals to retrieve information on the patterns of 
surgical care provided to patients with NSCLC (4). The report included more than 
11,000 patients with major pulmonary resections and showed that only 57.3% of 
patients had any mediastinal lymph nodes removed at the time of operation. 
The purposes of hilar and mediastinal lymph node dissection are accurate staging and 
the improvement of survival though better local control. The accurate staging is very 
important since several large-scale randomized trials have shown that postoperative 
adjuvant chemotherapy can improve the survival after surgery for NSCLC (5, 6). There 
is no doubt that complete lymph node dissection is the most accurate way to stage a 
patient’s disease and to determine which patients might benefit from adjuvant therapy. 
However, the extent of lymph node removal required and the impact of mediastinal 
lymph node removal on survival are still controversial. 
 In this chapter, the impact of lymph node dissection for NSCLC on the postoperative 
course, namely morbidity and survival, is reviewed and discussed. 
 
DEFFINITIONS 
Although nodal staging of NSCLC should be as accurate as possible, the surgical 





also noted that different terms are used to describe these surgical techniques. The 
definitions for various types of lymph node assessment were recently proposed by the 
council of the European Society for Thoracic Surgeons (7). 
Lymph node biopsy 
Only suspicious one or multiple lymph node(s) are biopsied to prove N1 or N2 disease. 
No systematic nodal dissection or biopsies are performed. The procedure is performed 
only to document lymph node metastasis when resection is not justified (Figure 1A). 
Lymph node sampling 
One or more lymph nodes are removed without any surrounding tissue, guided by 
preoperative or intraoperative findings that are thought to be representative (Figure 
1B). Systematic lymph node sampling means that a predetermined sampling of the 
lymph node stations is performed.  
Lymph node dissection 
The mediastinal tissue containing lymph nodes is dissected and removed systematically 
within anatomical landmarks (Figure 1C). In other words, all of the lymph nodes in the 
targeted compartment must be completely removed, as a block, together with 
surrounding adipose tissue (8). In general, following lobe-specific lymph node dissection 
should be performed: 
Right upper and middle lobe: 2R, 4R and 7; 
Right lower lobe: 4R, 7, 8, and 9; 
Left upper lobe: 5, 6 and 7; 
Left lower lobe: 7, 8 and 9; 
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preferable for patients with NSCLC because lymph node dissection (LND) can be 
associated with significantly increased morbidity and most recurrence are distant 
rather than local. In contrast, the standard approach for NSCLC in Japan has been 
pulmonary resection with systematic LND believing it can achieve better local control 
with negligible LND related morbidity.  
 Reasons not to perform LND include prolonging the operation and causing more 
operative complications such as recurrent nerve injury, chylothorax, bronchial 
devascularization, increased lymphatic drainage and bleeding. Izbicki et al. reported 
that LND did not increase the postoperative mortality or re-thoracotomy rate in their 
prospective randomized trial (9), but the mean duration of operation increased by 20 
min. Allen et al. reported 30-day operative data from 1,111 patients in a randomized 
trial comparing LNS and LND (10). Operative mortality was 2.0% for LNS and 0.8% for 
LND. Complication occurred in 38% of patients in each group. They also found an 
increase in operative time by 15 min. These studies suggested that LND adds little 
morbidity to a pulmonary resection for NSCLC although it requires additional operative 
time by 15-20 min. 
Survival 
So-called stage migration phenomenon between LNS and LND is an important factor 
that produces bias in retrospective studies. The best evidence is based on prospective 
randomized trials. Four prospective randomized trials to compare LNS and LND have 
been performed in Germany (9, 11), Japan (12), China (13) and USA (10, 14, 15). 
Inclusion criteria and methodologies are quite diverse among these studies, therefore, 
interpretation of each study has to be made carefully. 
 
① German study (9, 11) 





Number of patients: LNS (n = 93), LND (n = 76) 
Median follow-up: 47.5 months 
Survival: No difference 
This is the first prospective randomized trial comparing LNS and LND. Two hundred 
one patients were recruited for the study, but 32 patients were excluded from analysis 
due to various reasons. Somewhat LNS group included 17 patients more than LND 
group. About 60% of patients were node-negative pathologically in each group. There 
was no difference in survival between LNS and LND (p = 0.256). However, they found a 
borderline effect on survival (p = 0.058) in patients in patients with pN1 or single level 
pN2. They concluded that LND does not influence survival for patients without overt 
lymph node involvement but might provide benefit for patients with limited lymph node 
metastases. 
 
② Japanese study (12) 
Inclusion criteria: peripheral NSCLC less than 2 cm, cN0 based on CT 
Number of patients: LNS (n = 56), LND (n = 59) 
Median follow-up: 65 months 
Survival: 5-year survival LNS (84%) ≒ LND(81%) 
This is a small but well designed study comparing LNS and LND for patients with 
clinical N0 small (less than 2 cm) NSCLC. Pathological N2 was found in 14% and 12% of 
LNS group and LND group respectively. Survival was similar and no significant 
differences in the recurrence rate or survival was seen between the two groups. They 
concluded that clinically evaluated peripheral NSCLC smaller than 2 cm do not require 
LND.  
 





Inclusion criteria: resectable stage I-IIIA based on CT 
Number of patients: LNS (n =264), LND (n = 268) 
Median follow-up: more than 5 years 
Survival: median survival LND (59 months) > LNS (34 months) 
This is a larger trial of 532 patients with clinical stage I-IIIA NSCLC. As compared to 
the previous study, only about 30% of enrolled patients had stage I disease and 70% of 
them had nodal involvement. Survival was significantly better in LND group than in 
LNS group. When the two groups were compared in subgroups according to pathological 
stage, LND group provided significantly better survival than LNS group in stage I and 
stage IIIA. This study has been the only randomized trial suggesting the survival 
benefit of LND. 
 
④ American study (10, 14, 15) 
Inclusion criteria: N0 or non-hilar N1, T1 or T2 
                 All negative lymph nodes after systematic LNS 
Number of patients: LNS (n = 498), LND (n = 525) 
Median follow-up: 6.5 years 
Survival: median survival LNS (8.5 years) ≒ LND (8.1 years)  
The American College of Surgeons Oncology Group (ASOSOG) has performed a 
randomized multi-institutional prospective trial designed to determine whether 
long-term survival is affected by LND versus LNS at the time of pulmonary resection 
for NSCLC (ACOSOG Z0030 trial). Of note, this study was not a simple comparison of 
LNS and LND, but designed to assess the efficacy of additional LND when systematic 
LNS was negative. Systematic LNS was performed at 2R, 4R, 7, and 10R for right-sided 
tumors and 5, 6, 7, and 10L for left-sided tumors. Occult N2 disease was found in 4% by 





difference in local, regional, or distant recurrence between the two groups. They 
concluded that if systematic LNS is negative, LND does not improve survival in 
patients with early stage NSCLC. 
 
 Although these four studies were all prospective, the Chinese study was the only one 
which showed survival benefit of LND and other three studies showed no significant 
benefit. This difference may be derived from the different inclusion criteria used in each 
study. One can assume that LND may provide better local control and better survival 
than LNS only when there is positive lymph node dissected. In other words, when there 
is no positive lymph node dissected, LND would never be beneficial theoretically. 
Therefore, how many of the patients enrolled had positive lymph node would affect the 
outcome of these randomized trial comparing LNS and LND. The ratio of stage I (no 
lymph node involved) was about 60% in German study, 30% in Chinese study, and 80% 
in Japanese and American studies. Interestingly, Japanese and American studies (stage 
I, 80%) showed no survival benefit of LND, German study (stage I, 60%) showed 
borderline effect of LND on survival in patients with pN1 or single level pN2, and 
Chinese study (stage I, 30%) showed significant benefit of LND. In a non-randomized 
trial, Keller and his colleagues reported the comparison of survival among patients with 
stage II-IIIA NSCLC who underwent either LNS or LND in the Eastern Cooperative 
Oncology Group (ECOG) 3590 study. Median survival was 57.5 months for LND group 
and 29.2% for LNS group (p=0.004).(16) 
 ACOSOG Z0030 trial was the largest prospective randomized trial comparing LNS and 
LND and it cannot be underestimated. Only 4% of additional patients were found to 
have positive lymph nodes at LND that were missed at LNS. This study clearly showed 
that LND does not improve long-term survival in patients with early-stage (T1 or T2, 





rigorous systematic LNS. However, interpretation of this study has to be made carefully 
because the rigorous systematic LNS performed in this study would not be realistic in a 
clinical practice in most of the centers and countries. Despite the similar survival 
between LNS group and LND group, the authors of this study still recommended that 
all patients with resectable NSCLC should undergo LND because the procedure 
provides the patients with the most accurate staging and the opportunity for effective 














These three figures demonstrate the differences in the surgical technique for lymph 
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